Business Wire - October 27, 2006
"This substantial NIH award provides important validation of Argos' pioneering approach to personalized immunotherapy, which may have strong applications not only for HIV, but also for cancer and other infectious diseases," commented Dr. Charles Nicolette, Vice President of Research and Development at Argos and Principle Investigator for the contract. "Our unique technology utilizes patient-specific HIV antigens, allowing immune targeting of all private mutations that differ from patient to patient. This product candidate should induce immune responses perfectly matched to each individual's unique viral profile."
The contract, titled "HIV Vaccine Design and Development Teams," was issued by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services. The goal of this contract is to determine the immunogenicity of Argos' HIV immunotherapy candidate, currently in clinical trials, and subsequently develop even more potent next-generation product candidates. Therapies successfully identified and optimized through this contract would then be tested in a multi-center, randomized, placebo-controlled clinical study.
"Research in RNA-loaded dendritic cell immunotherapies for HIV treatment may provide the next important and effective treatment option for infectious disease," stated Dr. Jeff Jacobson, Chief of the Division of Infectious Diseases and HIV Medicine at Drexel University College of Medicine in Philadelphia, PA, and Principle Investigator for the clinical trial to be conducted under the contract. "We are therefore eager to participate in Argos' program and realize the promise of immunotherapy for HIV."
The five-year contract is valued at $21.3 million. Argos has partnered with a number of leading institutions who will participate in the development program. The award will cover substantially all of the costs associated with the development of the next-generation HIV immunotherapies, as well as portions of costs related to Argos' current HIV candidate development. Additionally, Argos retains commercial rights to any candidates that are developed through this funded research.
About RNA-loaded Dendritic Cell Technology
Argos' proprietary approach to personalized immunotherapy is based on optimizing a patient's own (autologous) dendritic cells to trigger a patient-specific immune response. To address the challenge of the unique genetic profile and mutations of each patient's disease, Argos loads the autologous dendritic cells with RNA, encoding the patient's unique antigens. Through this process, dendritic cells can coordinate immune responses to recognize the complete antigenic repertoire of a particular patient's cancer or infection, resulting in a specifically personalized immunotherapy.
About Argos Therapeutics, Inc.
Argos Therapeutics is developing breakthrough immunotherapies that target the unique features of a patient's disease. This new generation of personalized cancer and HIV therapeutics trains the immune system to recognize and attack the disease. Argos' scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases. www.argostherapeutics.com
Argos is a private biotechnology company headquartered in Research Triangle Park, NC. The company has multiple clinical trial programs in renal cell carcinoma (RCC), chronic lymphocytic leukemia (CLL), and human immunodeficiency virus (HIV) and has an ongoing co-development and commercialization alliance with the pharmaceutical division of Kirin Brewery Company, Limited.
CONTACT: MacDougall Biomedical Communications
Chris Erdman | 508-647-0209
or
Argos Therapeutics | Jeff Abbey, 919-287-6308
SOURCE: Argos Therapeutics, Inc.
061027
BW061019
Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .